Summary A novel anti-tumour amphibian oocyte RNase, ONCONASER (ONC), previously known as P-30 Protein, is in the clinical trials. The effect of ONC alone and in combination with lovastatin (LVT), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of mevalonate (MVA) and cholesterol synthesis pathway, in three human tumour cell lines ASPC-1 pancreatic, A-549 lung, and HT-520 lung carcinomas, has been presently studied. A synergism between ONC and LVT in inducing the cytostatic and cytotoxic effects was observed. The cytostatic effect, seen during the early phase of the treatment with this combination of drugs was manifested as prolongation of the cell cycle duration, especially of the GI phase; cell death was apparent after 72 h of treatment. The synergistic effect of ONC and LVT was also evident in the clonogenicity assays. Both LVT lactone and its in vitro activated beta-hydroxy acid form, alone and in respective combinations with ONC, exerted similar degree of growth suppression. The effects of both forms of LVT (used alone or in combination with ONC) were reversed by MVA, which suggests that HMG-CoA reductase inhibition is a primary mechanism of LVT action. The data indicate that the LVT lactone can be activated intracellularly by tumour cells studied, and that the combination of ONC with LVT can produce significantly enhanced anti-tumour activities.
Several years ago interesting observations were made that the malignant cell growth could be brought under control by the embryonic environment (Mintz & Illmensee, 1975; Papaioannou et al., 1975) . Introduction of tumour cells into the early mouse embryo resulted in development of a chimeric form in which a proportion of tumour cells was diminished compared to the normal cells when transplanted into the embryo. This suggested some embryonic regulatory mechanism, affecting tumour cell growth and differentiation (Papaioannou & Rossant, 1983 ).
An amphibian oocyte/early embryo ribonuclease named ONCONASER* (ONC) (previously known as P-30 Protein), a novel 12 kDa protein isolated from Rana pipiens eggs and early embryos (Ardelt et al., 1991) , appears to represent the first instance of a successful isolation, purification and characterization of the oocytic/early embryonic factor which is capable of controlling tumour cell growth. This protein, therefore, could be the molecular equivalent of at least part of the biological anti-tumour cell growth activities of the early embryonic tissues.
ONC has been reported to demonstrate anti-proliferative and cytotoxic activity against several human tumour cell lines in vitro (Darzynkiewicz et al., 1988) , and has also been shown to have a striking anti-tumour activity in vivo against the M109 Madison lung carcinoma in mice (Mikulski et al., 1990a) . Currently, ONC is in the Phase II human clinical trials and its activity is being assessed against a variety of human solid tumours.
When tested in vitro against human ASPC-1 pancreatic and A-549 lung adenocarcinoma cell lines, ONC interacted synergistically with tamoxifen and trifluoperazine, respectively (Mikulski et al., 1990b) . One of the possible mechanisms of action of tamoxifen and phenothiazine derivatives is an interference with a signal transduction involving calmodulin/Ca+2 and protein kinase C systems, and possibly an anti-oestrogen binding site/intracellular histamine receptor, resulting in an inhibition of the cell cycle progression (Mori et al., 1980; Gulino et al., 1986; Brandes et al., 1987) . Thus, the observed synergistic effects could be related to the effects of these drugs on the intracellular signal transduction pathways.
Guanosine triphosphate (GTP)-binding proteins (Gproteins), whether heterotrimeric or monomeric such as products of ras, rho, R-ras, or rab genes (Gilman, 1987; Finegold et al., 1990) , all require to be anchored via farnesylated carboxyl-terminal cysteine to the inner surface of the plasma membrane, in order to be active in signal transduction pathways (Finegold et al., 1990; Barbacid, 1987; Madaule & Axel, 1985; Chardin & Tavitian, 1986; Lowe et al., 1987; Touchot et al., 1987; Neer & Clapham, 1988; Schafer et al., 1989) . The 15-carbon farnesyl group is attached post-translationally to the sulfur of the carboxyl-terminal cysteine residue (Madaule & Axel, 1985; Schafer et al., 1989; Casey et al., 1989) . The gamma subunits of heterotrimeric G-proteins (Finegold et al., 1990 ) and nuclear lamins (Farnsworth et al., 1989; Vorburger et al., 1989) are also farnesylated, and in the case of lamin B, the terminal cysteine (after farnesylation) is carboxyl-methylated, in a cell cycle-dependent manner (Farnsworth et al., 1989; Chelsky et al., 1987) . The farnesylation process is inhibited by LVT (Repko & Maltese, 1989) , an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase. It was also observed that LVT suppresses cell proliferation by arresting cells in GI phase of the cell cycle (Jakobisiak et al., 1991) . It is likely, therefore, that the anti-proliferative effect of LVT is the consequence of the impairment of the signal transduction by this drug. Similar inhibition of cell proliferation has been previously observed with other HMG-CoA reductase inhibitors (QuesneyHuneeus et al., 1979; Sinensky & Logel, 1985; Doyle & Kandutsch, 1988 (Mikulski et al., 1990b) .
The determination of cell number, description of the MTT colorimetric assay, and statistical analysis were as previously published (Mikulski et al., 1990b) (Mikulski et al., 1990b Tables I-III) .
The equi-effective doses, i.e., ED50 values, were calculated for ONC alone, LVT beta-hydroxy acid and lactone alone, and for the combinations of ONC with both forms of LVT. In order to determine the type of interactions between different agents used in combinations, the interactions index has been used (Berenbaum, 1981) (Berenbaum, 1981) . Tables I, II and III present mean percentages of growth inhibition whereby varying doses of ONC were used either alone or in combination with various doses of both forms of LVT in ASPC-1, A-549 and HT-520 cells, respectively. The concentrations of LVT were selected based on our previous titration experiments to choose suboptimal doses, appropriate for detecting drug interactions. The mean values were derived from quadruplicate tests for each data point.
The interactions between ONC and both forms of LVT were clearly synergistic, as defined by Berenbaum (1981) , across varying concentrations of ONC, and designated by the capital letter 'S' in parentheses; letter 'A' designates an antagonism.
As can also be seen in Tables I-III , in all of the three cell lines the increased tumour cell growth inhibitory activities of the combination of ONC with both the beta-hydroxy acid and the lactone forms of LVT, when compared with ONC alone, were highly significantly different, with P values of 0.001 across varying concentrations of ONC. These results were reproducible in repeated experiments. Also, at certain concentrations of both forms of LVT, the activity of the combination of ONC with LVT-lactone was at least equal to that using the beta-hydroxy acid form of this drug. In fact, at the highest concentration of LVT used in ASPC-1 and A-549 lines, the activity of the combination of ONC with the lactone form of LVT was significantly greater than that with the acid form. These findings were observed consistently in repeated experiments.
Clonogenicity studies of ASPC-1 and A-549 cells confirmed the MTT assay-demonstrable synergistic interaction betwen ONC and LVT (Table IV) . Using trypan blue dye exclusion test in continuous cell culture over 144 h, it was clearly shown that the synergistic interaction manifested itself not only as a potentiated cytostatic effect, but also as an increased cytotoxic activity, which was time-dependent ( Figure 1) . Figure 2 shows cell cyle distribution of A-549 cells treated with ONC alone, lactone form of LVT alone, and the combination of both drugs. ONC alone (Figure 2b ) at 1 sg ml-' slightly increased the proportion of cells in G2/M phase, LVT alone at 5jM significantly decreased the proportion of cells in S phase from 33% to 13%, but had no effect at lower (2.5pM) concentration. When these data are compared to growth curves, the latter indicating a very significant (several-fold) slow-down of cell proliferation, it is evident that the suppression of cell growth by combination of ONC and LVT is a result of the prolongation of the overall cell cycle, rather than the specific arrest in particular phase of the cycle. GI phase, however, is more prolonged than the remaining portion of the cycle. This is in contrast to the LVT alone at 5jM which arrests cells quite specifically in G, phase.
While the cytostatic effects of the combined treatment with ONC and LVT are manifested early during the treatment (no cell death but significant inhibition of cell growth were seen during the first 72 h of treatment with 1 jig ml-1 of ONC + 5 or 7.5jiM of LVT), the cytotoxic effects became apparent, and progressively increased, later (Figure 1) .
To confirm the primary mechanism of action of LVT, HT-520 cells were subjected to both the acid and the lactone forms of LVT, with and without concomitant 200gM mevalonic acid lactone (MVA) (Jakobisiak et al., 1991) . MVA partially reversed both the LVT-induced cell growth inhibition and the interactive capability of LVT; these results are presented in Table V and expressed as ED50 values for the ONC + LVT combination in the MTT assay.
Discussion
Our present results show that the combinations of ONC with both acid and lactone forms of LVT demonstrate a synergistic anti-proliferative activity, as measured by the MTT colorimetric assay, clonogenicity studies and the trypan blue dye exclusion assessments. The flow cytometric studies indicated that the cytostatic effect induced by treatment with LVT + ONC results predominantly from the extension of duration of all phases of the cell cycle. GI phase, however, appears to be more prolonged than S and G2/M by ONC + LVT combination, compared to the untreated cells. Interstingly, whereas LVT alone at 5gM concentration produced the GI cell arrest, the addition of ONC partially abolished the Glspecific effect of LVT, presumably by entrapping the cells in other phases of the cell cycle.
We have also demonstrated that these activites of LVT alone and in combination are reversible by MVA, thus confirming a primary mechanism of action of LVT as an inhibitor of HMG-CoA reductase. The findings of at least equal degree of anti-tumour activitiy exerted by LVT lactone suggest that this form of LVT can be activated by tumour cells, and that the in vitro activation of LVT lactone may not always be necessary. These findings have very important practical applications with regard to the potential use of LVT in in vivo systemic cancer treatment.
The ability of MVA, but not cholesterol, to reverse the HMG-CoA reductase inhibitor-induced cell growth arrest and DNA synthesis inhibition (Quesney-Huneeus et al., 1979) , as well as a direct stimulation of DNA synthesis in mouse fibroblasts upon microinjection of recombinant p21 ras proteins (Stacey & Kung, 1984) , and the GI phase arrest of growing cells and the reversal of a transformed phenotype induced by microinjection of monoclonal anti-p21 antibodies (Kung et al., 1986) , all strongly suggest an essential cell growth regulatory activity of the inner plasma membraneanchored p21 ras proteins. However, since LVT could interfere with the function of over 40 other proteins known to be normally isoprenylated (Madaule & Axel, 1985; Chardin & Tavitian, 1986; Touchot et al., 1987; Casey et al., 1989; Farnsworth et al., 1989; Schmidt et al., 1984) , it is also possible that the observed anti-proliferative activity of this drug may be as well related to the interference with the function of other than, or in addition to, p21 ras protein(s), e.g., nuclear scaffold lamins (Farnsworth et al., 1989; Vorburger et al., 1989) . These latter proteins undergo cell-cyclical proteolytic degradation which is associated with a generation of a 46 kD protein possessing a nucleoside triphosphatase activity. This activity, in turn, is thought to participate in nucleocytoplasmic transport of RNA (Tokes & Clawson, 1989) . It has been previously demonstrated that, by analogy to the factor a of Saccharomyces cerevisiae and p21 ras proteins, the carboxyl-terminal cysteine of lamin B is farnesylated and its carboxyl group methylated (Anderegg et al., 1988; Farnsworth et al., 1989) and, interestingly, in a cell cycle-dependent manner (Chelsky et al., 1987) . All of these findings emphasise our lack of knowledge of a precise mechanism of action of LVT.
The observed synergism between ONC and LVT might be related to their effects on RNA metabolism: ONC through its ribonucleotyic activity (Ardelt et al., 1991) capable of destroying specific species of RNA, and LVT acting via interference with the lamin proteins-related nucleocytoplasmic RNA transport (Tokes & Clawson, 1989) . Both actions could conceivably inhibit cell growth.
An increased expression of a mutated ('activated') ras gene product(s) has been observed in a variety of human malignancies, including adenocarcinoma of the lung (Rodenhuis et al., 1987) , pre-malignant and high grade lesions of bladder carcinoma (Viola et al., 1985) , colon carcinoma (Forrester et al., 1987) , acute myeloid leukaemia (Bos et al., 1985) , ovarian serous cystadenocarcinoma (Feig et al., 1984) , and melanoma (Albino et al., 1984) . Using monoclonal antibodies specific for synthetic eight residues peptide containing amino acids corresponding to positions 10-17 of the mutated in positon 12 Ha-ras gene product (valine substituted for glycine), it was shown that mutated ras gene expression is markedly increased in most of the human colon and mammary carcinomas, but not in normal colonic and mammary epithelia, nor benign fibroadenoma and/or fibrocystic disease (Hand et al., 1984) .
Although an increased expression of normal (not mutated) human Ha-ras proto-oncogene has been shown to be capable of inducing tumourigenic transformation of mammalian cells (Chang et al., 1982) , such an enhanced expression appears to be infrequent in human neoplasia, with an approximate incidence of 1% (Barbacid, 1987) , and in some instances it may only induce immortalisation of cells (Spandidos & Wilkie, 1984) .
In majority of human tumours, the 'activation' (mutation) of ras genes did not seem to correlate with the histopathological properties of the tumour, and was not associated with any specific type of neoplasia (Barbacid, 1987; Forrester et al., 1987) . The 'activated' ras genes were detectable ony in some, but not other, tumour deposits of human metastatic melanoma isolated from the same patient, thus reflecting a significant tumour cell heterogeneity with regard to ras genes' expression (Albino et al., 1984) . Although the activated ras genes may not be able to induce malignant transformation by themselves, they can be effective as co-inducers of such transformation in cooperation with, e.g., nuclear oncogenes such as c-myc (Land et al., 1983; Weinberg, 1989) . All of these findings point to the still poorly understood relative clinical importance of both normally expressed and mutated ras gene products.
The observed synergism between ONC (currently being evaluated in Phase II human clinical trials) and LVT (which has been used in the treatment of certain forms of hypercholesterolemia), as reflected by both the increased cytostatic and cytotoxic effects, suggests that this combination should be investigated in vivo, including human trials. It may offer a new therapeutic approach against notoriously resistant human solid tumours.
